RT Journal Article SR Electronic T1 Association of Serum HB-EGF Value and Response to Chemotherapy in Patients with Recurrent Ovarian Cancer JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 4347 OP 4351 DO 10.21873/anticanres.12735 VO 38 IS 7 A1 DAISUKE IZUCHI A1 SATOSHI FUKAGAWA A1 FUSANORI YOTSUMOTO A1 KOICHIRO SHIGEKAWA A1 KENICHI YOSHIKAWA A1 TOYOFUMI HIRAKAWA A1 CHIHIRO KIYOSHIMA A1 NAM SUNG OUK A1 DAICHI URUSHIYAMA A1 TAKAHIRO KATSUDA A1 KOHEI MIYATA A1 TOMOHIRO ITO A1 MASAMITSU KURAKAZU A1 RYOTA ARAKI A1 AYAKO SANUI A1 DAISUKE MIYAHARA A1 MASAHARU MURATA A1 HIROKO ITO A1 KYOKO SHIROTA A1 MASAHIDE KUROKI A1 SHIN'ICHIRO YASUNAGA A1 SHINGO MIYAMOTO YR 2018 UL http://ar.iiarjournals.org/content/38/7/4347.abstract AB Background/Aim: Many anticancer agents including molecularly-targeted drugs have been developed for ovarian cancer. However, the prognosis of recurrent ovarian cancer remains extremely poor. Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is reported as a rational target for ovarian cancer therapy. Moreover, serum HB-EGF expression is recognized as a biomarker in patients with primary ovarian cancer. Materials and Methods: We analysed serum samples with recurrent ovarian cancer at the Fukuoka University Hospital from April 2009 to March 2014. To assess the clinical significance of serum HB-EGF in recurrent ovarian cancer, the association between serum HB-EGF levels and prognosis in patients with recurrent ovarian cancer was examined using ELISA. Results: Patients with high serum HB-EGF expression showed a significantly poor response to second-line chemotherapeutic agents compared with patients with low HB-EGF levels. Conclusion: HB-EGF expression in serum may be a potential therapeutic indicator for novel HB-EGF-targeted therapy in recurrent ovarian cancer.